Alle Storys
Folgen
Keine Story von sanofi-aventis Group mehr verpassen.

sanofi-aventis Group

Sanofi pasteur to License Micro-Delivery Technology From BD Medical

Lyon, France (ots/PRNewswire)

Sanofi pasteur, the vaccines
business of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY),
has entered into an agreement with BD (Becton, Dickinson and Company)
(NYSE: BDX) to license the Micro-Delivery technology of BD
Medical-Pharmaceutical Systems for use in the administration of
sanofi pasteur's human vaccine products.
Sanofi pasteur's vaccines have traditionally been given via
intramuscular injection. This BD technology provides a new method of
delivering vaccines into the skin. The results of early-phase
clinical research have shown that utilization of this new technology
has the potential to improve the immunogenicity and efficacy of the
delivered vaccine.
The BD Micro-Delivery System is designed to be pre-filled with
vaccine and to easily and reliably deliver the vaccine to the target
area. The tiny micro-needle used in the Micro-Delivery System is as
thin as a human hair.
Under the terms of the agreement, BD will provide sanofi pasteur
with a license to the BD Micro-Delivery System in the field of human
vaccines. The parties will continue to work together to further
demonstrate the Micro-Delivery System's applicability to delivering a
wide variety of vaccines, including the influenza vaccine that is now
being evaluated in human clinical trials conducted in conjunction
with the U.S. National Institute of Allergy and Infectious Diseases
(NIAID).
Per the agreement, BD will be compensated for use of the
Micro-Delivery System by sanofi pasteur, who will develop,
manufacture and commercialize the Micro-Delivery vaccine based
products developed in this collaboration. Further financial details
of the agreement are not disclosed.
This collaboration is part of sanofi pasteur's ongoing corporate
commitment to protect and improve human health worldwide by providing
superior, innovative vaccines for the prevention and treatment of
disease.
BD is a medical technology company that serves healthcare
institutions, life science researchers, clinical laboratories,
industry and the general public. BD manufactures and sells a broad
range of medical supplies, devices, laboratory equipment and
diagnostic products. To learn more about BD, please visit www.bd.com.
About sanofi-aventis
The sanofi-aventis Group is the world's third-largest
pharmaceutical company, ranking number one in Europe. Backed by a
world-class R&D organization, sanofi-aventis is developing leading
positions in seven major therapeutic areas: cardiovascular disease,
thrombosis, oncology, metabolic diseases, central nervous system,
internal medicine, and vaccines. The sanofi-aventis Group is listed
in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi pasteur, the vaccines business of the sanofi-aventis Group,
sold nearly a billion doses of vaccine in 2004, making it possible to
protect more than 500 million people across the globe, which is about
1.4 million per day. The company offers the broadest range of
vaccines, providing protection against 20 bacterial and viral
diseases. For more information, please visit: www.sanofipasteur.com
Forward Looking Statements
This press release contains forward-looking statements as defined
in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are statements that are not historical
facts. These statements include financial projections and estimates
and their underlying assumptions, statements regarding plans,
objectives and expectations with respect to future operations,
products and services, and statements regarding future performance.
Forward-looking statements are generally identified by the words
"expect," "anticipates," "believes," "intends," "estimates," "plans"
and similar expressions. Although sanofi-aventis' management believes
that the expectations reflected in such forward-looking statements
are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond the control of sanofi-aventis, that could cause actual results
and developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and
statements. These risks and uncertainties include those discussed or
identified in the public filings with the SEC and the AMF made by
sanofi-aventis, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in
sanofi-aventis' annual report on Form 20-F for the year ended
December 31, 2004. Other than as required by applicable law,
sanofi-aventis does not undertake any obligation to update or revise
any forward-looking information or statements.
Sanofi-aventis Group subsidiaries in the United States include
Sanofi-Synthelabo Inc., Aventis Pharmaceuticals Inc. and Sanofi
Pasteur Inc.
    sanofi pasteur                            sanofi pasteur
    Alain BERNAL                              Len LAVENDA
    Vice-President Corporate Communications   U.S. Media Relations
    Tel: +33-(0)4-37-37-78-97                 Tel: +1-570-839-4446
    Fax: +33-(0)4-37-37-72-76                  Len.Lavenda@sanofipasteur.com

Contact:

sanofi pasteur: Alain BERNAL, Vice-President Corporate
Communications, Tel: +33-(0)4-37-37-78-97, Fax: +33-(0)4-37-37-72-76
or sanofi pasteur: Len LAVENDA, U.S. Media Relations, Tel:
+1-570-839-4446, Len.Lavenda@sanofipasteur.com

Weitere Storys: sanofi-aventis Group
Weitere Storys: sanofi-aventis Group